Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressive Symptoms in Patients With Parkinson's Disease

28 ottobre 2026 aggiornato da: Ho-Won Lee

Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressive Symptoms in Patients With Parkinson's Disease : A Single-Center, Randomized, Double-Blinded, Sham-Controlled, Parallel-Design, Investigator-Initiated Exploratory Clinical Trial

The purpose of this study is to evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) in improving depressive symptoms in patients with Parkinson's Disease(PD).

Participants will be randomly assigned to either an active rTMS group or a sham-control group.

The study aims to evaluate the efficacy and feasibility of a neuronavigation-guided bilateral M1 rTMS protocol.

Panoramica dello studio

Stato

Iscrizione su invito

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Antidepressants and other psychotropic medications must have been stable for 4 weeks before baseline and remain unchanged during the study

At each clinical assessment, the time of the most recent dopaminergic medication dose and the participant's clinical medication state (ON or OFF) will be recorded. Whenever feasible, follow-up assessments will be performed at a similar time relative to the participant's usual dopaminergic medication schedule as at baseline.

Tipo di studio

Interventistico

Iscrizione (Stimato)

50

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Buk-gu
      • Daegu, Buk-gu, Corea del Sud, 41404
        • Kyungpook National University Chilgok Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 40 anni a 90 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Willing and able to provide written informed consent
  • Male or female aged 40 to 90 years
  • Diagnosed with Parkinson's disease with depressive symptoms
  • Hoehn and Yahr stage 1 to 3
  • On stable Parkinson's disease medication for at least 3 months prior to screening, with no planned dose increase during the study period
  • Clinically significant depressive symptoms (BDI-II score ≥14) confirmed by clinician interview, without major psychiatric conditions that may confound their assessment
  • Able to read and write Korean and capable of independently completing questionnaires

Exclusion Criteria:

  • History of epilepsy
  • Parkinson's disease caused by cerebrovascular disease, CNS infection, intoxication, or traumatic brain injury
  • Diagnosed with Parkinson-plus syndromes (multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies etc.)
  • Clinically significant abnormal laboratory values (AST, ALT, or total bilirubin > 2.5 x ULN)
  • Major psychiatric disorders other than depressive disorders (e.g., bipolar disorder, psychotic disorders) that may interfere with study participation or assessment of depressive symptoms
  • Unable to follow instructions or communicate
  • Pregnant, breastfeeding, or women of childbearing potential
  • Febrile patients
  • Patients with artificial hip joint implants
  • Presence of conductive, ferromagnetic, or magnetically sensitive metal near the head or treatment coil (e.g., cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils)
  • Cardiac disease, especially patients with pacemakers
  • Corrected or uncorrected visual acuity less than 0.5
  • Use of drug infusion pumps or hearing aids
  • Patients with acute illness
  • Patients taking tricyclic antidepressants, neuroleptics, or other medications that may lower seizure threshold
  • History of increased intracranial pressure or head trauma
  • Evidence of external wounds on brain or neck
  • Prominent psychotic symptoms other than depression (high NPI scores for hallucinations, delusions, mania)
  • History of schizophrenia, bipolar disorder, or substance abuse
  • Suicidal ideation (BDI-II item 9 score of 2 or 3)
  • History of or planned deep brain stimulation or stereotactic surgery (pallidotomy, thalamotomy)
  • Any participant deemed ineligible by the investigator, including those with medical conditions that may increase risk or interfere with study evaluation
  • Currently enrolled in another clinical trial or used investigational drug/device within 30 days or 5 half-lives prior to consent

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Real rTMS

Participants receive active repetitive transcranial magnetic stimulation (rTMS) to bilateral primary motor cortex (M1), guided by neuronavigation (BrainEyes). Stimulation is delivered at 10 Hz, 90% of resting motor threshold (RMT), 1,000 pulses per session, once daily for 5 consecutive weekdays. Participants continue their existing Parkinson's disease medication throughout the study.

High-frequency rTMS is delivered to bilateral primary motor cortex (M1) using neuronavigation guidance (BrainEyes). Parameters: 10 Hz, 90% of resting motor threshold (RMT), 50 pulses per train, 55-second inter-train interval, 20 trains per session, 1,000 pulses per session, once daily for 5 consecutive weekdays.

Comparatore fittizio: Sham rTMS

Participants receive sham repetitive transcranial magnetic stimulation (rTMS) to bilateral primary motor cortex (M1), guided by neuronavigation (BrainEyes). The coil is tilted 90 degrees perpendicular to the scalp so that no magnetic field is delivered to the cortex. The same click sound and scalp sensation are maintained to preserve participant blinding. The session parameters are identical to the active rTMS group (10 Hz, 1,000 pulses per session, once daily for 5 consecutive weekdays). Participants continue their existing Parkinson's disease medication throughout the study.

Sham rTMS is delivered with the coil tilted 90 degrees perpendicular to the scalp to prevent magnetic field delivery to the cortex. The same click sound and scalp sensation are maintained. Session parameters are identical to active rTMS group.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change From Baseline in Beck Depression Inventory-II (BDI-II) Total Score
Lasso di tempo: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session

The BDI-II is a 21-item self-reported questionnaire assessing the severity of depressive symptoms. Each item is scored from 0 to 3, yielding a total score ranging from 0 to 63, with higher scores indicating greater severity of depressive symptoms. Changes in BDI-II total score from baseline (T0) will be compared between the real rTMS and sham rTMS groups after treatment (T1) and at the follow-up assessment (T2).

Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change From Baseline in Neuropsychiatric Inventory (NPI) Scores
Lasso di tempo: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session

The NPI is a caregiver- or informant-based assessment of neuropsychiatric symptoms. It evaluates 12 neuropsychiatric symptom domains based on symptom frequency and severity. Changes in NPI scores from baseline (T0) will be compared between the real rTMS and sham rTMS groups after treatment (T1) and at the follow-up assessment (T2).

Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Parkinson's Disease Questionnaire-39 (PDQ-39) Scores
Lasso di tempo: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session

Disease-specific questionnaire assessing quality of life in Parkinson's disease patients across 8 domains: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. Scores range from 0 to 100; higher scores indicate worse quality of life.

Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Scores
Lasso di tempo: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session

Comprehensive clinician-administered scale assessing motor and non-motor symptoms of Parkinson's disease across 6 subscales: non-motor experiences of daily living, motor experiences of daily living, motor examination, motor complications, Hoehn and Yahr staging, and Schwab and England ADL scale. Higher scores indicate greater disease severity.

Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Parkinson's Disease Sleep Scale (PDSS) Scores
Lasso di tempo: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session

Self-reported scale assessing sleep disturbances in Parkinson's disease patients, consisting of 15 items rated on a 5-point Likert scale (0-4). Covers three domains: nocturnal motor symptoms, PD-specific nocturnal symptoms, and sleep-specific disturbances. Higher scores indicate more frequent sleep disturbances.

Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Toronto Alexithymia Scale-20 Korean Version (TAS-20-K) Scores
Lasso di tempo: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session

Korean validated version of the Toronto Alexithymia Scale consisting of 20 items rated on a 5-point Likert scale, assessing three factors: difficulty identifying feelings (DIF), difficulty describing feelings (DDF), and externally oriented thinking (EOT). Higher total scores indicate greater alexithymia.

Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Montreal Cognitive Assessment (MoCA) Scores
Lasso di tempo: Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session

Brief cognitive screening tool assessing multiple cognitive domains including attention, concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Scores range from 0 to 30; higher scores indicate better cognitive function.

Baseline, immediately after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Facial Expression Measures on FaceReader Analysis
Lasso di tempo: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session

Automated facial expression analysis using FaceReader software to quantitatively assess facial action units (AUs) and emotional expression patterns. Participants perform facial emotion recognition and imitation tasks. Measures include response speed, latency, accuracy, and facial expression accuracy based on Action Unit analysis.

Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Eye Movement Measures on Eye-Tracking
Lasso di tempo: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session

Quantitative assessment of eye movements using screen-based Tobii Pro Spark. Measures include gaze speed, gaze position, gaze duration, gaze latency, and pupil size during task performance, providing objective evaluation of oculomotor function.

Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Muscle Activity Measured by Electromyography (EMG)
Lasso di tempo: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session

Muscle activity is measured using DELSYS Trigno Avanti Sensor and Trigno Quattro Sensor attached to the skin with medical tape. Wireless measurement technology enables free movement during task performance, with real-time data collection via dedicated software.

Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Postural Stability and Balance Measures on BT4 Balance Assessment
Lasso di tempo: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session

Quantitative assessment of postural stability using BT4 balance evaluation system, measuring center of pressure (COP) displacement during standing. Assesses limits of stability in anterior, posterior, and lateral directions, and COP movement during Romberg test under eyes-open and eyes-closed conditions.

Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Body Composition Measured by Bioelectrical Impedance Analysis (InBody)
Lasso di tempo: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session

Basic physical information is collected using InBody580 with 4-pole 8-point tactile electrode method. Bioelectrical impedance is measured across 3 frequency bands (5kHz, 50kHz, 250kHz) in 5 body segments (right arm, left arm, trunk, right leg, left leg), yielding 15 impedance measurements.

Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Electrodermal Activity Measured by Galvanic Skin Response (GSR)
Lasso di tempo: Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session

Electrodermal activity is measured using the Shimmer Consensys GSR Development Kit, which records skin conductance changes between electrodes via wireless sensors. Sweat gland activation in response to internal or external stimuli alters skin moisture and ionic balance, producing measurable changes in electrodermal activity.

Baseline, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session
Change in Brain Structure and Connectivity on MRI
Lasso di tempo: Baseline and 1 week (±2 days) after the final stimulation session

Neuroimaging assessment of brain structure using MRI with two sequences: T1-weighted and T2-weighted structural imaging. Used to evaluate structural changes before and after rTMS treatment, and to guide neuronavigation-based TMS targeting.

Baseline and 1 week (±2 days) after the final stimulation session
Change in Plasma Biomarker Concentrations
Lasso di tempo: Baseline and immediately after the final stimulation session

Quantitative measurement of candidate plasma biomarkers including Amyloid beta 40/42, Tau, phosphorylated Tau (p-Tau), and Neurofilament light chain (NfL) using antibody-based quantitative analysis methods (SIMOA, Luminex, or ELISA).

Baseline and immediately after the final stimulation session
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Lasso di tempo: From the first stimulation session to the final stimulation session, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session

Safety will be assessed by the number and proportion of participants experiencing treatment-emergent adverse events (TEAEs) from the initiation of rTMS or sham stimulation through the final follow-up assessment. Adverse events will be summarized by event type, severity, and relationship to the investigational device. Serious adverse events, adverse device effects, and discontinuations due to adverse events will also be recorded and summarized by treatment group.

From the first stimulation session to the final stimulation session, 1 week (±2 days) after the final stimulation session, and 4 weeks (±7 days) after the final stimulation session

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Ho-Won Lee, MD, Kyungpook National University Chilgok Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 maggio 2026

Completamento primario (Stimato)

27 novembre 2026

Completamento dello studio (Stimato)

31 dicembre 2026

Date di iscrizione allo studio

Primo inviato

28 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

28 aprile 2026

Primo Inserito (Effettivo)

6 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

29 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • KNUCH 2025-08-046-006

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be publicly shared to protect the privacy of the participants. However, de-identified data may be available from the principal investigator upon reasonable request for research purposes, subject to institutional review board approval.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .